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Usefulness of Serum Leucine-Rich Alpha-2 Glycoprotein as a 
Disease Activity Biomarker in Patients with Rheumatoid Arthritis 
Our study aimed to investigate whether serum leucine-rich alpha-2-glycoprotein (LRG) 
levels are elevated in patients with rheumatoid arthritis (RA). In addition, we assessed their 
correlation with disease activity parameters and pro-inflammatory cytokine, tumor 
necrosis factor-α (TNF-α). Our study included 69 patients with RA and 48 age- and sex- 
matched healthy controls. Serum concentrations of TNF-α and LRG were determined by 
enzyme-linked immunosorbent assay. Serum LRG concentrations were significantly 
elevated in patients with RA compared with those in healthy controls (30.8 ± 14.4 vs. 
22.2 ± 6.1 ng/mL; P < 0.001). In patients with RA, serum LRG levels were found to be 
correlated with disease activity score 28 (DAS28), erythrocyte sedimentation rate, and 
C-reactive protein levels (γ = 0.671; γ = 0.612; and γ = 0.601, P < 0.001, respectively), 
but not with serum TNF-α levels. Serum LRG levels in patients with an active disease status 
(DAS28 ≥ 2.6) were significantly higher than those in remission (DAS28 < 2.6) (36.45 ±  
14.36 vs. 24.63 ± 8.81 ng/mL; P < 0.001). Our findings suggest that serum LRG could 
contribute to the inflammatory process independent of TNF-α and it may be a novel 
biomarker for assessing inflammatory activity in patients with RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease 
that primarily affects the synovial lining of the diarthrodial joints 
(1). The primary features of RA are synovial hyperplasia, inflam-
matory cell infiltration of the synovium, neoangiogenesis, im-
balance between pro- and anti-inflammatory cytokines, and 
progressive destruction of articular cartilage and bone (1). Re-
cent treatment guidelines emphasize early and aggressive treat-
ment and aim for remission as a therapeutic target (2, 3). To 
improve outcomes, patients must be closely monitored for dis-
ease activity at each clinician visit, and disease-modifying anti-
rheumatic drugs (DMARDs) must be appropriately adminis-
tered. Although erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) levels are routinely measured in clinical 
practice to assess the disease activity of RA, their usage has been 
limited, as they are often discordant with each other and their 
values are even in the normal range in approximately 50% of 
active patients with RA (4, 5). For this reason, many investiga-
tors aimed to identify reliable biomarkers to monitor disease 
activity.
 Leucine-rich alpha-2 glycoprotein (LRG) is an approximately 
50 kDa glycoprotein that contains a leucine-rich motif (6, 7). 
The function of LRG is not fully understood; however, its ex-
pression in various cells has been reported (8-11). In a recent 
study that involved proteome analysis of the serum of patients 
with chronic inflammatory diseases (inflammatory bowel dis-
ease, rheumatoid arthritis, and Behçet disease), a significant el-
evation of serum LRG concentrations was noted, suggesting 
that LRG may be a useful biomarker for inflammatory condi-
tions (12). Recent research demonstrated that LRG expression 
in colon cells was induced by interleukin (IL)-6, tumor-necrosis 
factor (TNF)-α, and IL-22 (8), which also play pivotal roles in 
the pathophysiology of RA (13, 14). 
 The aims of our study were to compare the serum LRG levels 
in patients with RA with those of healthy controls and to com-
pare the usefulness of serum LRG as a marker of disease activity 
in patients with RA with that of other disease activity parame-
ters and pro-inflammatory cytokine, TNF-α.
MATERIALS AND METHODS
Study design and subjects
This cross-sectional study included 69 patients with RA and 48 
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age- and sex- matched healthy controls. All patients were diag-
nosed with RA between June 2012 and May 2013 at an outpa-
tient rheumatology clinic (Chung-Ang University College of 
Medicine, Seoul, Korea). All patients fulfilled the 1987 revised 
American College of Rheumatology (15) or the 2010 revised 
American College of Rheumatology/European League Against 
Rheumatism classification criteria for RA (16). Patients with 
acute infection, malignancies, or combined autoimmune dis-
eases were excluded to remove possible biases. Forty-eight age- 
and sex- matched healthy individuals who visited the Health 
Examination Center for medical check-ups were included as 
the control group. 
Clinical and laboratory assessments
Patient age, sex, medication history, height, body weight, dis-
ease duration, and extra-articular manifestations of RA were 
recorded. Clinical and laboratory data were collected during 
blood sampling. The number of tender and swollen joints and 
visual analogue scores judged globally by the physician and 
subjects were assessed. All joint examinations were conducted 
by the same rheumatologist. Complete blood count, biochemi-
cal analysis, IgM type of rheumatoid factor, anti-cyclic citrulli-
nated peptide antibody, and anti-nuclear antibody were assess-
ed. ESR was determined from whole blood using Westergren 
method (Afifax, Padova, Italy), and CRP concentration was as-
sessed in serum via a nephelometric method (Beckman Coult-
er, Inc., Fullerton, CA, USA). Disease Activity Score 28 (DAS28) 
was calculated to determine RA disease activity (17). Patients 
were divided into two subgroups according to their disease ac-
tivity as follows: inactive group, DAS28 ≤ 2.6; active group, DAS28 
> 2.6 (17).
Measurement of serum LRG and cytokines
Venous blood samples were obtained from patients with RA 
and healthy controls. The collected serum samples were centri-
fuged at 1,500 rpm for 15 min, divided into aliquots, and stored 
frozen at -80°C until used. Serum LRG (IBL Co., Ltd., Gunma, 
Japan) and TNF-α (R&D Systems, Inc., Minneapolis, MN, USA) 
levels were measured via enzyme-linked immunosorbent assay 
(ELISA) according to the manufacturer’s protocol. Intra- and 
inter-assay coefficients of variation of LRG were 3.0%-4.9% and 
4.2%-5.1%, respectively, and those of TNF-α were 4.6%-5.2% 
and 5.4%-7.4%, respectively. The coefficients of determination 
(R2) were 0.9973 and 0.9943 for LRG and TNF-α, respectively. 
All samples were analyzed in duplicate.
Statistical analysis
All statistical analyses were conducted using the IBM SPSS Sta-
tistics software version 20.0 (IBM Corp., Armonk, NY, USA). Con-
tinuous variables were expressed as mean ± standard deviations. 
Mean differences between continuous variables were evaluat-
ed using Student’s t-test and Mann-Whitney U-test. Categorical 
variables were analyzed via the chi-square test. The ability of 
LRG level to distinguish RA from healthy controls was evaluat-
ed using a receiver-operating characteristic (ROC) analysis. Cor-
relations between parameter studies were calculated with the 
Pearson’s correlation coefficient. In all analyses, a P value < 0.05 
was considered statistically significant. 
Ethics statement
This study was approved by the institutional review board of 
Chung-Ang University Hospital (C2013169-1129). Informed 
consent was confirmed by the board, and we obtained informed 
consent from all patients and controls in the study.
RESULTS
Serum concentrations of LRG in healthy controls and 
patients with RA
Our study included 69 patients with RA and 48 healthy controls. 
There was no statistically significant differences in the mean 
age or the sex ratio between the two groups (age, 56.0 ± 13.5 vs. 
55.1 ± 3.3 yr; P = 0.635; female ratio 53/69 [76.8%] vs. 29/48 
[60.4%)]; P = 0.057). The CRP levels in patients with RA were 
significantly higher than those in the healthy controls (1.07 ±  
2.30 vs. 0.15 ± 0.22 mg/dL; P = 0.001). However, there were no 
significant differences in CRP levels between the inactive RA 
group and the healthy control group (0.24 ± 0.21 vs. 0.15 ± 0.22 
mL; P = 1.000). Serum LRG levels were significantly elevated in 
patients with RA compared with those in the healthy controls 
(30.8 ± 14.4 vs. 22.2 ± 6.1 ng/mL; P < 0.001; Fig. 1). ROC analy-
sis for LRG to discriminate between RA and healthy control re-
sulted in an area under the curve (AUC) of 0.712 (95% CI, 0.619-
0.804) and an optimal cut-point at 27 ng/mL. With that cut-off 
level, the sensitivity was 53.6% and the specificity was 85.4% 
(Fig. 2). 
Characteristics of patients with RA and comparison 
according to disease activity status
The clinical features and laboratory values of patients with RA 
are described in Table 1. All patients with RA were divided into 
an active group (n = 36) or an inactive group (n = 33) according 
to their DAS28 scores. Patients in the active group had higher 
levels of ESR, CRP, and DAS28 than those in the inactive group. 
Mean serum LRG levels were higher in the active group than in 
the inactive group (36.5 ± 16.2 vs. 30.8 ± 14.4 ng/mL; P < 0.001; 
Fig. 3). Mean LRG levels in both the active and inactive groups 
significantly differed from those in the healthy controls (P < 0.001 
and P = 0.044, respectively; Fig. 3). However, mean serum TNF-α 
levels were not significantly different between these two groups.
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Fig. 1. Serum leucine-rich alpha-2 glycoprotein (LRG) levels in rheumatoid arthritis 
(RA) patients and controls. Mean LRG concentrations were significantly elevated in 
the serum of patients with RA compared with those in healthy controls (P < 0.001).
Fig. 2. Receiver-operating characteristic (ROC) analysis for leucine-rich alpha-2 gly-
coprotein (LRG) to discriminate between rheumatoid arthritis (RA) and healthy control. 
It resulted in an area under curve (AUC) of 0.712 (95% CI, 0.619-0.804) and an op-
timal cut-point at 27 ng/mL. With that cut-off level, the sensitivity was 53.6% and the 
specificity was 85.4%.
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Table 1. Demographics and clinical characteristics of patients with rheumatoid arthritis according to disease activity
Parameters Total (n = 69) Active (n = 36) Inactive (n = 33) P value*
Age (yr) 56.0 ± 13.5 55.0 ± 13.2 57.1 ± 13.9 0.511
Female, No. (%) 53 (76.8) 29 (80.6) 24 (72.7) 0.441
Disease duration (yr) 5.3 ± 8.9 5.4 ± 10.2 5.2 ± 7.2 0.915
DAS 28 3.04 ± 1.58 4.14 ± 1.38 1.84 ± 0.61 < 0.001
ESR (mm/hr) 26.3 ± 25.2 39 ± 29 13 ± 8 < 0.001
CRP (mg/dL) 1.07 ± 2.30 1.84 ± 3.00 0.24 ± 0.21 0.003
WBC (/μL) 7,428 ± 2,582 7,638 ± 2,130 7,200 ± 3,017 0.485
Total cholesterol (mg/dL) 176 ± 30 177 ± 26 175 ± 35 0.759
Glucocorticoid (PD, mg/day) 5.2 ± 3.6 6.2 ± 4.2 4.0 ± 2.2 0.022
RF positivity, No. (%) 58 (84.1) 33 (91.7) 25 (78.1) 0.172
ACPA positivity, No. (%) 43 (62.3) 24 (80.0) 19 (70.4) 0.399
Methotrexate use, No. (%) 51 (73.9) 28 (77.8) 23 (69.7) 0.584
Sulfasalazine use, No. (%) 17 (24.6) 10 (27.8) 7 (21.2) 0.585
Hydroxychloroquine use, No. (%) 18 (26.1) 9 (25.0) 9 (27.3) 0.83
Leflunomide use, No. (%) 14 (20.3) 8 (22.2) 6 (18.2) 0.677
TNF-α level (ng/mL) 2.72 ± 5.42 2.16 ± 2.40 3.33 ± 7.44 0.372
*P values were compared between active group and inactive group. DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; WBC, 
white blood cell; PD, prednisolone; RF, rheumatoid factor; APCA, anti-citrullinated protein antibody; TNF, tumor necrosis factor.
Correlations between serum LRG and TNF-α levels and 
disease activity parameters in patients with RA
We analyzed the relationship between serum concentrations of 
LRG and other disease activity parameters in patients with RA. 
The serum LRG levels were significantly correlated with DAS28 
(γ = 0.671; P < 0.001; Fig. 4A), ESR (γ = 0.612; P < 0.001; Fig. 4B), 
CRP (γ = 0.671; P < 0.001; Fig. 4C), and the number of tender 
joints (γ = 0.554; P < 0.001; Fig. 4D) and swollen joints (γ = 0.514; 
P < 0.001; Fig 4E). However, serum LRG levels were not corre-
lated with serum TNF-α levels (γ = 0.007; P = 0.954) and neu-
trophil count (γ = 0.099; P = 0.420).
DISCUSSION
In the present study, we demonstrated that the serum concen-
tration of LRG was significantly elevated in patients with RA 
compared with that in the healthy controls. Serum LRG levels 
were found to be correlated with DAS28, suggesting that LRG 
could be a useful marker for assessing disease activity in patients 
with RA.
 LRG is a serum protein, which was the first isolated from hu-
man serum in 1977 (7). The amino acid sequence of LRG was 
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Fig. 3. Differences in serum concentrations of leucine-rich alpha-2 glycoprotein (LRG) 
between patients with active and inactive rheumatoid arthritis (RA) and healthy con-
trols. Serum concentrations of LRG in the active RA group are higher than those in 
the inactive RA group and controls (P < 0.001). Patients with inactive RA show higher 
LRG levels than the controls (P = 0.044).
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Fig. 4. Correlations between disease activity pa-
rameters and serum concentrations of leucine-
rich alpha-2 glycoprotein (LRG) in patients with 
rheumatoid arthritis (RA). Serum levels of LRG are 
positively correlated with disease activity score 
28 (DAS28) (γ = 0.671, P < 0.001), (A) erythro-
cyte sedimentation rate (ESR) (γ = 0.612, P < 
0.001), (B) C-reactive protein (CRP) (γ = 0.601, 
P < 0.001), (C) number of tender joints (γ = 0.554, 
P < 0.001), (D) and number of swollen joints (γ = 
0.514, P < 0.001), (E).
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identified in 1985, and showed 66 leucine residues among 312 
amino acid residues. LRG contains a leucine-rich repeat that 
consists of periodic eight-unit repeats of a 3 amino acid sequence 
(leucine-proline-asparagine) (6). Although its function and re-
gulation are unclear, LRG has been detected in the sera of heal-
thy individuals. Studies have reported that LRG is expressed in 
brain astrocyte, hepatocyte, and neutrophil (9-11). In a mouse 
study published in 2002, LRG expression was found to be a pos-
sible indication of inflammation and granulocyte differentia-
tion (11). Shirai et al. (10) demonstrated that LRG expression in 
HepG2 cells was up-regulated by IL-6, and its secretory pattern 
was similar to that of acute-phase proteins such as CRP. 
 Cytokines play a critical role in the pathogenesis of RA. Pro-
inflammatory cytokines such as TNF-α, IL-1, IL-6, IL-17, and 
IL-33, are activated in the synovium by various cell populations 
(14, 18). In our study, serum TNF-α levels were not correlated 
with DAS28 or serum LRG levels. Previous studies showed dis-
crepancy about whether serum TNF-α levels were correlated 
with clinical disease activity (19-21). A recent study showed that 
LRG expression in colon cells was induced by IL-6, TNF-α, and 
IL-22 (8). However, in a previous proteomic analysis of serum 
from patients with RA, Behçet disease, and Crohn disease, se-
rum LRG levels were not found to correlate with serum IL-6 
levels (12). When considered together, serum LRG levels might 
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be regulated in part cytokines other than TNF-α or IL-6 in pa-
tients with RA. Future studies that involve additional cytokine 
analysis will be needed to clarify the regulatory mechanisms of 
circulating LRG levels in RA. 
 Previous studies suggested that LRG may be a protein secret-
ed by the inflammatory process and that reflects the inflamma-
tory burden (10). However, LRG has been shown to bind cyto-
chrome C and has been hypothesized to play a role in cell sur-
vival (22). A recent study demonstrated that LRG promotes pa-
thological angiogenesis via the transforming growth factor-β 
signaling pathway (23). To date, there have been no reports re-
garding the expression of LRG in the synovium of RA patients. 
Regarding the contribution of neoangiogenesis and defective 
apoptosis to perpetuation of chronic synovial inflammation in 
RA (24, 25), LRG may play an important role in the pathogene-
sis of RA. Further studies are warranted to elucidate the role of 
LRG in the pathophysiology of RA.
 LRG may be a useful biomarker in various conditions such as 
infection, malignancies, and chronic inflammatory diseases. 
Kentsis et al. (26) suggested urine LRG as a useful biomarker to 
differentiate patients with appendicitis from those with acute 
abdominal pain. Elevated serum LRG levels have been observed 
in ovarian, biliary tract, colorectal, and non-small cell lung can-
cers (27-30). These findings indicate that serum LRG levels could 
increase in various inflammatory and pathologic conditions. 
Hence, elevated serum LRG levels may not be used as a specific 
diagnostic marker of certain diseases. However, serum LRG con-
centrations were significantly elevated in patients with ulcer-
ative colitis compared with those in patients in remission. Simi-
larly, patients with a DAS28 score > 2.6 were found to have high-
er serum LRG levels than those with a DAS28 score ≤ 2.6 (Fig. 
2). Moreover, the present study demonstrated that serum LRG 
levels are correlated with disease activity indicators such as DAS-
28, ESR, CRP, and the number of tender and swollen joints, which 
indicates that measuring serum LRG levels could be helpful for 
assessing disease activity in patients with RA.
 In our study, ROC analyses showed that LRG has an ability to 
distinguish between RA and normal controls. While CRP levels 
in patients with inactive RA were not significantly different from 
those in the healthy controls, the LRG level in inactive RA was 
significantly higher than that in healthy control. Therefore we 
think that serum LRG levels more than 27 ng/mL could be an 
indication for RA exacerbation before clinical manifestation. 
However, considering the cost of measuring LRG levels by ELI-
SA, future study to investigate whether LRG is superior to cheap 
acute phase reactants (ESR and CRP) should be performed to 
apply LRG in the clinical practice. 
 We expected that the serum LRG levels in patients with RA 
were correlated with neutrophil count because LRG expression 
was up-regulated during neutrophilic differentiation (11). How-
ever, no correlation was found between serum LRG level and 
neutrophil count in patients with RA. The reason is unclear, yet 
we may consider that LRG had little connection with neutro-
phils in RA pathogenesis because LRG can be expressed in oth-
er cells (8-10). The use of prednisolone would be another con-
founding factor, in that it induces neutrophilia independent to 
the pathophysiology of RA (31). 
 Our study has several limitations. First, the study population 
was not large enough to achieve statistical significance. Howev-
er, our study population was > 2-folds the size of the previous 
study (12). Second, due to the cross-sectional design, the causal 
relationship and serial change in serum LRG level according to 
the change in the disease activity of RA could not be defined. 
Also, considering the percentage of RA patients in remission, 
disease activity (DAS28) of our study population was not so high. 
Further large-sized, longitudinal study can clarify the LRG con-
centration at different disease activity status (remission, mild, 
moderate and high disease activity) as well as serial change of 
LRG levels according to the change of disease activity. Third, 
the levels of other cytokines, including IL-1, IL-6, and IL-17, in 
the pathophysiology of RA were not measured, and their rela-
tions to LRG were not analyzed. 
 Our study demonstrated that serum LRG levels were elevat-
ed in patients with RA compared with those in the healthy con-
trols, and that serum LRG level is correlated with disease activi-
ty parameters of RA independent of TNF-α. These findings sug-
gest that LRG reflects the burden of systemic inflammation in 
RA and may play a role in the inflammatory process. Serum LRG 
could be a useful disease activity marker in patients with RA.
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